Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q15744
UPID:
CEBPE_HUMAN
Alternative names:
-
Alternative UPACC:
Q15744; Q15745; Q8IYI2; Q99803
Background:
CCAAT/enhancer-binding protein epsilon plays a pivotal role in myeloid differentiation, acting as a transcriptional activator. It binds to specific DNA motifs, facilitating the transition from promyelocyte to myelocyte, a critical step in the development of immune cells.
Therapeutic significance:
Linked to Specific granule deficiency 1 and Immunodeficiency 108 with autoinflammation, understanding the role of CCAAT/enhancer-binding protein epsilon could open doors to potential therapeutic strategies for these immune disorders.